Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it’s time to act now

키워드

참고문헌 (114)

1. Shapiro JL, "The third opium war? : understanding China through history", Horizons, 13, pp.52~65 (2019)
2. Jayawardana S, "Global consumption of prescription opioid analgesics between 2009-2019 : a country-level observational study", EClinicalMedicine, 42, pp.101198~ (2021)
3. Rudd RA, "Increases in drug and opioid overdose deaths--United States, 2000-2014", MMWR Morb Mortal Wkly Rep, 64, pp.1378~1382 (2016)
4. Soffin EM, "The prescription opioid crisis : role of the anaesthesiologist in reducing opioid use and misuse", Br J Anaesth, 122, pp.e198~e208 (2019)
5. Yang J, "The modified WHO analgesic ladder : is it appropriate for chronic non-cancer pain", J Pain Res, 13, pp.411~417 (2020)
6. Woolf CJ, "Capturing novel non-opioid pain targets", Biol Psychiatry, 87, pp.74~81 (2020)
7. Siegel RL, "Cancer statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
8. Collett BJ, "Chronic opioid therapy for non-cancer pain", Br J Anaesth, 87, pp.133~143 (2001)
9. Classification of chronic pain, "Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy", Pain Suppl, 3, pp.S1~S226 (1986)
10. Uritsky TJ, "Opioid stewardship : building on antibiotic stewardship principles", J Pain Palliat Care Pharmacother, 34, pp.181~183 (2020)
11. "Core elements of hospital antibiotic stewardship programs" (2019)[URL]
12. "Opioid stewardship" (2017)[URL]
13. Dowell D, "CDC guideline for prescribing opioids for chronic pain--United States, 2016", JAMA, 315, pp.1624~1645 (2016)
14. National Quality Forum (NQF), "National Quality Partners PlaybookTM: opioid stewardship", NQF, ~ (2018)
15. "Stem the tide:opioid stewardship measurement implementation guide" (2020)[URL]
16. Trescot AM, "Opioid pharmacology", Pain Physician, 11(2 Suppl), pp.S133~S153 (2008)
17. World Health Organization (WHO), "Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence", WHO Press, 5~ (2009)
18. World Health Organization (WHO), "ICD-10. International statistical classification of diseases and related health problems. 10th ed", WHO Press, 289~292 (2016)
19. "International Classification of Diseases 11th edition: the global standard for diagnostic health information" (2022)[URL]
20. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders. 5th ed", American Psychiatric Association Publishing, 1~947 (2013)
21. Brady KT, "Prescription opioid misuse, abuse, and treatment in the United States : an update", Am J Psychiatry, 173, pp.18~26 (2016)
22. Volkow ND, "Opioid abuse in chronic pain--misconceptions and mitigation strategies", N Engl J Med, 374, pp.1253~1263 (2016)
23. Ballantyne JC, "Opioid dependence and addiction during opioid treatment of chronic pain", Pain, 129, pp.235~255 (2007)
24. Srivastava AB, "New directions in the treatment of opioid withdrawal", Lancet, 395, pp.1938~1948 (2020)
25. Kosten TR, "Review article : effective management of opioid withdrawal symptoms : a gateway to opioid dependence treatment", Am J Addict, 28, pp.55~62 (2019)
26. Inciardi JA, "The diversion of prescription opioid analgesics", Law Enforc Exec Forum, 7, pp.127~141 (2007)
27. Iwanicki JL, "Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States", PLoS One, 11, pp.e0167499~ (2016)
28. Berge KH, "Diversion of drugs within health care facilities, a multiplevictim crime : patterns of diversion, scope, consequences, detection, and prevention", Mayo Clin Proc, 87, pp.674~682 (2012)
29. Perry JC, "Drug diversion detection", Nurs Manage, 50, pp.16~21 (2019)
30. O’Brien T, "European Pain Federation position paper on appropriate opioid use in chronic pain management", Eur J Pain, 21, pp.3~19 (2017)
31. Nafziger AN, "Opioid therapy in acute and chronic pain", J Clin Pharmacol, 58, pp.1111~1122 (2018)
32. GustorffB, "The absence of acute tolerance during remifentanil infusion in volunteers", Anesth Analg, 94, pp.1223~1228 (2002)
33. Cortínez LI, "No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia", Br J Anaesth, 87, pp.866~869 (2001)
34. Guignard B, "Acute opioid tolerance : intraoperative remifentanil increases postoperative pain and morphine requirement", Anesthesiology, 93, pp.409~417 (2000)
35. Yu EH, "Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain?", Anaesthesia, 71, pp.1347~1362 (2016)
36. Ilkjaer S, "Effect of systemic N-methyl-D-aspartate receptor antagonist(ketamine)on primary and secondary hyperalgesia in humans", Br J Anaesth, 76, pp.829~834 (1996)
37. Felsby S, "NMDA receptor blockade in chronic neuropathic pain : a comparison of ketamine and magnesium chloride", Pain, 64, pp.283~291 (1996)
38. Ramasubbu C, "Pharmacological treatment of opioid-induced hyperalgesia : a review of the evidence", J Pain Palliat Care Pharmacother, 25, pp.219~230 (2011)
39. 김경훈, "Safe Sedation and Hypnosis using Dexmedetomidine for Minimally Invasive Spine Surgery in a Prone Position", The Korean Journal of Pain, 27(4), pp.313~320 (2014), 대한통증학회
40. Zhao Y, "Mechanisms of dexmedetomidine in neuropathic pain", Front Neurosci, 14, pp.330~ (2020)
41. Grape S, "Intraoperative analgesia with remifentanil vs. dexmedetomidine:a systematic review and meta-analysis with trial sequential analysis", Anaesthesia, 74, pp.793~800 (2019)
42. 김경훈, "All about pain pharmacology: what pain physicians should know", The Korean Journal of Pain, 33(2), pp.108~120 (2020), 대한통증학회[DOI]
43. Conrad KA, "Effects of ketorolac tromethamine on hemostasis in volunteers", Clin Pharmacol Ther, 43, pp.542~546 (1988)
44. Meera Shrestha, "Modalities in managing postherpetic neuralgia", The Korean Journal of Pain, 31(4), pp.235~243 (2018), 대한통증학회
45. Raja SN, "Opioids versus antidepressants in postherpetic neuralgia : a randomized, placebocontrolled trial", Neurology, 59, pp.1015~1021 (2002)
46. Adejumo AC, "Predictors, rates, and trends of opioid use disorder among patients hospitalized with chronic pancreatitis", Ann Gastroenterol, 34, pp.262~272 (2021)
47. Toskes PP, "Alcohol consumption and chronic pancreatitis", Mayo Clin Proc, 76, pp.241~ (2001)
48. Berna C, "Tapering long-term opioid therapy in chronic noncancer pain : evidence and recommendations for everyday practice", Mayo Clin Proc, 90, pp.828~842 (2015)
49. Palmer G, "Complex regional pain syndrome", Aust Prescr, 38, pp.82~86 (2015)
50. Donegan D, "Opioid-induced adrenal insufficiency", Mayo Clin Proc, 93, pp.937~944 (2018)
51. Su Jung Lee, "Successful removal of permanent spinal cord stimulators in patients with complex regional pain syndrome after complete relief of pain", The Korean Journal of Pain, 32(1), pp.47~50 (2019), 대한통증학회[DOI]
52. Koulousakis A, "Intrathecal opioids for intractable pain syndromes", Acta Neurochir Suppl, 97(Pt 1), pp.43~48 (2007)
53. Won-Sung Kim, "Percutaneous osteoplasty for painful bony lesions: a technical survey", The Korean Journal of Pain, 34(4), pp.375~393 (2021), 대한통증학회[DOI]
54. Lipton A, "The science and practice of bone health in oncology : managing bone loss and metastasis in patients with solid tumors", J Natl Compr Canc Netw, 7(Suppl 7), pp.S1~S9 (2009)
55. Yang S, "Prevalence and risk factors of adhesive capsulitis of the shoulder after breast cancer treatment", Support Care Cancer, 25, pp.1317~1322 (2017)
56. Del Fabbro E, "Assessment and management of chemical coping in patients with cancer", J Clin Oncol, 32, pp.1734~1738 (2014)
57. Pergolizzi JV Jr, "Opioid therapy in cancer patients and survivors at risk of addiction, misuse or complex dependency", Front Pain Res (Lausanne), 2, pp.691720~ (2021)
58. Goodlev ER, "Managing cancer pain, monitoring for cancer recurrence, and mitigating risk of opioid use disorders : a team-based, interdisciplinary approach to cancer survivorship", J Palliat Med, 22, pp.1308~1317 (2019)
59. Trescot AM, "Opioids in the management of chronic non-cancer pain : an update of American Society of the Interventional Pain Physicians’(ASIPP)Guidelines", Pain Physician, 11(2 Suppl), pp.S5~S62 (2008)
60. "Drugs of abuse. A DEA resource guide: 2020ed" (2020)[URL]
61. Pagel JF, "Medications for the treatment of sleep disorders : an overview", Prim Care Companion J Clin Psychiatry, 3, pp.118~125 (2001)
62. Busse JW, "Guideline for opioid therapy and chronic noncancer pain", CMAJ, 189, pp.E659~E666 (2017)
63. Barker C, "Problematic pain-redefining how we view pain", Br J Pain, 8, pp.9~15 (2014)
64. Chou R, "Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain", J Pain, 10, pp.113~130 (2009)
65. "The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update", J Addict Med, 14(2S Suppl 1), pp.1~91 (2020)
66. Crotty K, "Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder", J Addict Med, 14, pp.99~112 (2020)
67. "FDA Drug Safety Communications: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning" (2016)[URL]
68. "Medications to treat opioid use disorder research report: how much does opioid treatment cost?" (2016)[URL]
69. "Federal guidelines for opioid treatment programs" (2015)[URL]
70. Johnson RE, "A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence", N Engl J Med, 343, pp.1290~1297 (2000)
71. "Risk assessment: safe opioid prescribing tools" (2019)[URL]
72. Webster LR, "Predicting aberrant behaviors in opioid-treated patients : preliminary validation of the Opioid Risk Tool", Pain Med, 6, pp.432~442 (2005)
73. Butler SF, "Validation of the revised Screener and Opioid Assessment for Patients with Pain(SOAPP-R)", J Pain, 9, pp.360~372 (2008)
74. Coambs RE, "The SISAP : a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain within general medical practice", Pain Res Manag, 1, pp.155~162 (1996)
75. Belgrade MJ, "The DIRE score : predicting outcomes of opioid prescribing for chronic pain", J Pain, 7, pp.671~681 (2006)
76. Compton PA, "Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance", J Pain Symptom Manage, 36, pp.383~395 (2008)
77. Butler SF, "Development and validation of the Current Opioid Misuse Measure", Pain, 130, pp.144~156 (2007)
78. Adams LL, "Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients", J Pain Symptom Manage, 27, pp.440~459 (2004)
79. Compton P, "Screening for addiction in patients with chronic pain and “problematic” substance use: evaluation of a pilot assessment tool", J Pain Symptom Manage, 16, pp.355~363 (1998)
80. Passik SD, "Monitoring outcomes during long-term opioid therapy for noncancer pain : results with the Pain Assessment and Documentation Tool", J Opioid Manag, 1, pp.257~266 (2005)
81. Wu SM, "The addiction behaviors checklist : validation of a new clinician-based measure of inappropriate opioid use in chronic pain", J Pain Symptom Manage, 32, pp.342~351 (2006)
82. Brown RL, "Conjoint screening questionnaires for alcohol and other drug abuse : criterion validity in a primary care practice", Wis Med J, 94, pp.135~140 (1995)
83. "Screening, brief intervention, and referral to treatment (SBIRT)" (2022)[URL]
84. Bastiaens L, "The RAFFT as a screening tool for adult substance use disorders", Am J Drug Alcohol Abuse, 28, pp.681~691 (2002)
85. Skinner HA, "The drug abuse screening test", Addict Behav, 7, pp.363~371 (1982)
86. Bush K, "The AUDIT alcohol consumption questions (AUDITC):an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test", Arch Intern Med, 158, pp.1789~1795 (1998)
87. Berman AH, "The self-report Drug Use Disorders Identification Test : Extended(DUDIT-E) : reliability, validity, and motivational index", J Subst Abuse Treat, 32, pp.357~369 (2007)
88. Wakeman SE, "Diagnosis and treatment of opioid use disorder in 2020", JAMA, 323, pp.2082~2083 (2020)
89. "Information about medication-assisted treatment (MAT)" (2019)[URL]
90. Sordo L, "Mortality risk during and after opioid substitution treatment : systematic review and meta-analysis of cohort studies", BMJ, 357, pp.j1550~ (2017)
91. Whelan PJ, "Buprenorphine vs methadone treatment : a review of evidence in both developed and developing worlds", J Neurosci Rural Pract, 3, pp.45~50 (2012)
92. Oakley B, "Managing opioid withdrawal precipitated by buprenorphine with buprenorphine", Drug Alcohol Rev, 40, pp.567~571 (2021)
93. Connery HS, "Medication-assisted treatment of opioid use disorder : review of the evidence and future directions", Harv Rev Psychiatry, 23, pp.63~75 (2015)
94. Patterson Silver Wolf DA, "Treatment resistant opioid use disorder(TROUD) : definition, rationale, and recommendations", J Neurol Sci, 411, pp.116718~ (2020)
95. "Protracted withdrawal. Substance abuse treatment advisory. News for the treatment field. 2010; 9:1-8. U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration (SAMHSA). HHS Publication No. (SMA) 10-4554" (2010)[URL]
96. Nicholson SC, "Risk evaluation and mitigation strategies(REMS) : educating the prescriber", Drug Saf, 35, pp.91~104 (2012)
97. "Introduction of DUR" (2012)[URL]
98. "Introduction of narcotics handling report system (NHRS)" (2015)[URL]
99. "Drug utilization review (DUR)" (2020)[URL]
100. Baldini A, "A review of potential adverse effects of long-term opioid therapy : a practitioner’s guide", Prim Care Companion CNS Disord, 14, pp.11m01326~ (2012)
101. Petzke F, "Long-term opioid therapy for chronic noncancer pain : second update of the German guidelines", Pain Rep, 5, pp.e840~ (2020)
102. "Royal College of General Practitioners: guidance for the use of methadone for the treatment of opioid dependence in primary care" (2005)[URL]
103. Sofuoglu M, "Pharmacological and behavioral treatment of opioid use disorder", Psychiatr Res Clin Pract, 1, pp.4~15 (2019)
104. Reddy S, "The effect of oral methadone on the QTc interval in advanced cancer patients : a prospective pilot study", J Palliat Med, 13, pp.33~38 (2010)
105. Khanna IK, "Buprenorphine-an attractive opioid with underutilized potential in treatment of chronic pain", J Pain Res, 8, pp.859~870 (2015)
106. Fischer A, "Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine", naloxone tablet formulation in healthy volunteers, 2015, pp.41, 79~84
107. "Medication-assisted treatment (MAT):MAT medications, counseling, and related conditions – naltrexone" (2022)[URL]
108. Kunzler NM, "Opioid withdrawal precipitated by long-acting antagonists", J Emerg Med, 58, pp.245~253 (2020)
109. Wesson DR, "The clinical opiate withdrawal scale(COWS)", J Psychoactive Drugs, 35, pp.253~259 (2003)
110. Kim Joungyoun, "Recent trends in opioid prescriptions in Korea from 2002 to 2015 based on the Korean NHIS-NSC cohort", Epidemiology and Health, 44, pp.1~8 (2022), 한국역학회[DOI]
111. Oh TK, "Trends in chronic opioid use and association with five-year survival in South Korea : a population-based cohort study", Br J Anaesth, 123, pp.655~663 (2019)
112. Cho NR, "Trends in opioid prescribing practices in South Korea, 2009-2019 : are we safe from an opioid epidemic", PLoS One, 16, pp.e0250972~ (2021)
113. Noh Y, "Trends in potentially inappropriate opioid prescribing and associated risk factors among Korean noncancer patients prescribed noninjectable opioid analgesics", Ther Adv Drug Saf, 13, pp.20420986221091001~ (2022)
114. "Example of request for supply of narcotic drugs" (2021)[URL]

관련 논문AI추천